for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MediGene AG

MDG1k.DE

Latest Trade

5.60EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.32

 - 

10.85

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
5.60
Open
--
Volume
--
3M AVG Volume
0.74
Today's High
--
Today's Low
--
52 Week High
10.85
52 Week Low
5.32
Shares Out (MIL)
24.56
Market Cap (MIL)
137.80
Forward P/E
-5.12
Dividend (Yield %)
--

Latest Developments

More

Medigene 9-Month EBITDA Loss Of EUR 18.6 Mln

Medigene H1 EBITDA Loss Of EUR 13.2 Mln

Medigene: Clinical Data From Interim Analysis Of Phase I/II Trial With DC Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MediGene AG

Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for adoptive T-cell therapy as treatments for patients with tumor burdens; Dendritic cell (DC) vaccines for the treatment of low tumor burdens, such as minimal residual disease or for use in combination therapies, and T-cell-specific monoclonal antibodies (TABS) to identify T cells based on their T-cell receptors. The Company operates offices in Martinsried in Germany, as well as in Washington DC and San Diego in the United States.

Industry

Biotechnology & Drugs

Contact Info

Lochhamer Strasse 11

+49.89.2000330

https://www.medigene.de/

Executive Leadership

Horst Domdey

Chairman of the Supervisory Board

Dolores J. Schendel

Chairman of the Executive Management Board, Chief Executive Officer, Chief Scientific Officer

Antoinette Hiebeler-Hasner

Deputy Chairman of the Supervisory Board

Axel-Sven Malkomes

Chief Financial Officer and Chief Business Development Officer

Kai Pinkernell

Member of the Executive Management Board, Chief Medical Officer, Chief Development Officer

Key Stats

2.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (EUR)

2016

-0.480

2017

-0.630

2018

-0.720

2019(E)

-1.096
Price To Earnings (TTM)
--
Price To Sales (TTM)
20.58
Price To Book (MRQ)
1.61
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.90
LT Debt To Equity (MRQ)
6.60
Return on Investment (TTM)
-21.80
Return on Equity (TTM)
-19.79

Latest News

Latest News

BRIEF -Medigene Raises 2018 Guidance After H1 Results

* NOW EXPECTS TO GENERATE TOTAL 2018 REVENUE OF BETWEEN EUR 9.5 - 10.5 MILLION

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

Medigene broadens alliance on T-cell receptors with Bluebird Bio

German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

BRIEF-Medigene AG Medigene Appoints Dr. Kai Pinkernell To Executive Management Board As Cmo/Cdo

* MEDIGENE AG: MEDIGENE APPOINTS DR. KAI PINKERNELL TO EXECUTIVE MANAGEMENT BOARD AS CMO/CDO Source text for Eikon: Further company coverage:

BRIEF-Medigene AG Says ‍Planned 2018 EBITDA Loss Of EUR 21 - 23 Mln​

* PTA-NEWS: MEDIGENE AG: MEDIGENE PUBLISHES 2017 ANNUAL REPORT AND ANNOUNCES START OF CLINICAL TRIAL WITH TCR IMMUNOTHERAPY MDG1011

BRIEF-Medigene Receives Approvals For First Clinical Trial With MDG1011

* SAYS RECEIVES APPROVALS FOR ITS FIRST CLINICAL TRIAL WITH TCR THERAPY MDG1011

BRIEF-Medigene Strengthens Its Patent Portfolio With US Patent On Tagged TCR

* MEDIGENE STRENGTHENS ITS PATENT PORTFOLIO WITH A US PATENT ON A TAGGED TCR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Medigene, RXi To Collaborate On Therapeutic T Cells

* MEDIGENE COLLABORATES WITH RXI PHARMACEUTICALS TO FURTHER SHARPEN ITS THERAPEUTIC T CELLS

BRIEF-Medigene Sells US-Rights For Veregen, Raises 2017 Guidance

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SELLS US-RIGHTS FOR VEREGEN® AND RAISES FINANCIAL GUIDANCE 2017

BRIEF-Medigene to issue new shares to settle Trianta milestone payment

* Announces issuance and number of new shares to settle last Trianta milestone payment

BRIEF-Medigene H1 total revenue at EUR 4.9 mln​

* H1 REVENUE FROM CORE BUSINESS IMMUNOTHERAPIES (BLUEBIRD BIO PARTNERSHIP) AMOUNTS TO EUR2,252 K (6M 2016: EUR0 K)

BRIEF-Medigene submits CTA for its first TCR clinical trial

* PTA-ADHOC: MEDIGENE AG: MEDIGENE SUBMITS CTA FOR ITS FIRST TCR CLINICAL TRIAL AND ANNOUNCES MILESTONE PAYMENT

BRIEF-Medigene says shareholders approve all resolutions

* Says shareholders approve all resolutions with a high majority

BRIEF-Medigene sticks with guidance after Q1 operating loss

* Financial guidance for 2017 confirmed Source text for Eikon: Further company coverage:

BRIEF-Medigene COO steps down

* Says Dave Lemus steps down as COO and continues cooperation in an advisory role Source text for Eikon: Further company coverage:

BRIEF-Medigene revises collaboration with Mitsui Norin

* Today announced a new contractual arrangement with Mitsui Norin Co. Ltd, regarding its drug Veregen

BRIEF-Medigene FY total revenue increases 43 pct to 9.8 mln euros

* FY total revenue increases 43 pct to 9.8 million euros ($10.58 million)

Medigene eyeing more immunotherapy deals after Bluebird pact

German biotech firm Medigene said it is drawing more interest from prospective alliance partners for its technology to boost the immune response to cancer after its deal with U.S. peer Bluebird Bio.

BRIEF-Medigene appoints Thomas Taapken as Chief Financial Officer

* Medigene appoints Thomas Taapken as chief financial officer

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up